Related Experiment Video

Updated: Jul 12, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease

Hyun Phil Shin1, Joung Il Lee, Joo-Ho Jung

  • 1Department of Internal Medicine, East-West Neo Medical Center, Kyung Hee University College of Medicine, Gangdong-gu, Seoul 134-090, Korea.

Digestive Diseases and Sciences
|September 4, 2007
PubMed

Insights

Matrix metalloproteinase-3 (MMP-3) gene polymorphism may influence liver fibrosis progression in chronic hepatitis B. Lower platelet counts were observed in MMP-3 5A allele carriers, suggesting a potential role in liver cirrhosis development.

Area of Science:

  • Hepatology
  • Genetics
  • Immunology

Background:

  • Liver fibrosis progression is a significant complication in chronic hepatitis B (CHB) patients.
  • Matrix metalloproteinases (MMPs), particularly MMP-3, are implicated in the pathogenesis of liver fibrosis.
  • Understanding genetic factors influencing fibrosis progression is crucial for patient management.

Purpose of the Study:

  • To investigate the association between MMP-3 gene polymorphism and liver cirrhosis in Korean patients with CHB.
  • To explore the relationship between MMP-3 genotypes and clinical parameters, such as platelet count, in CHB patients.

Main Methods:

  • Genomic DNA was collected from 127 CHB patients, 92 with hepatitis B virus (HBV)-related liver cirrhosis (HBV-LC), and 146 healthy controls.
  • MMP-3 polymorphism was analyzed using polymerase-chain reaction (PCR)-based assays.
  • Statistical analyses were performed to compare genotype distributions and clinical parameters among the groups.

Main Results:

  • No significant differences in MMP-3 genotype distributions were found among the CHB, HBV-LC, and healthy control groups.
  • A statistically significant lower peripheral platelet count was observed in MMP-3 5A allele carriers compared to 6A homozygotes within the HBV-LC group (P = 0.02).
  • MMP-3 promoter polymorphism (rs3025058) was associated with lower platelet counts in 5A carriers, correlating with advanced liver cirrhosis.

Conclusions:

  • MMP-3 gene polymorphism, specifically the 5A allele, may be associated with reduced platelet counts in HBV-related liver cirrhosis patients.
  • This finding suggests a potential role for MMP-3 polymorphism in the progression of liver cirrhosis.
  • Further research with larger cohorts is warranted to elucidate the precise role of MMP-3 gene polymorphism in liver fibrosis progression in CHB.

Related Concept Videos

Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...